Alveolar nitric oxide combined with eosinophilic granulocyte assay guides glucocorticoid use in patients with acute exacerbation of chronic obstructive pulmonary disease
Phase 1
Completed
- Conditions
- chronic obstructive pulmonary disease (COPD)
- Registration Number
- ChiCTR2400088787
- Lead Sponsor
- The Second People's Hospital of Fuyang City
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) Healthy people; patients over 40 years of age with stable COPD diagnosed by pulmonary function; patients with a clear diagnosis and no history of acute exacerbation in the last 3 months, and patients with regular inhalation medication for AECOPD. All those who voluntarily participate and can complete the trial.<br>
Exclusion Criteria
Patients with chronic cough (more than 8 weeks of illness), bronchial asthma, bronchiectasis, lung cancer, sleep apnea-hypopnea syndrome caused by various causes; <br>Patients with long-term oral or intravenous glucocorticoids, allergy to glucocorticoids, coronary heart disease, hypertension, heart failure and diabetes, liver and kidney diseases.<br>
Study & Design
- Study Type
- Treatment study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method alveolar nitric oxide;eosinophil count;
- Secondary Outcome Measures
Name Time Method